Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative methylene blue for prevention of postoperative delirium after joint replacement in older adults
ChiCTR2300074038Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methylene blue in postoperative delirium (POD) (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Incidence of delirium within 5 days after surgery. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
methylene blue
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on ChiCTR2300074038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074038.